Drugs / Gadolinium
Trials 12
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT00978562 | Aug 2009 → Dec 2015 | brain neoplasm | OHSU Knight Cancer Institute | Completed | No outcome recorded |
| Phase 12 trials | ||||||
| Phase 1 | NCT02531880 | Nov 2024 → Jul 2030 expected | epilepsy | National Institute of Neurological Disorders and Stroke (NINDS) | Recruiting | No outcome recorded |
| Phase 1 | NCT04264143 | Mar 2020 → Apr 2022 | diffuse intrinsic pontine glioma | Luca Szalontay | Completed | No outcome recorded |
| Phase 1/23 trials | ||||||
| Phase 1/2 | NCT02074293 | Jan → Jun 2016 | cervical dystonia | li nguyen | Unknown | No outcome recorded |
| Phase 1/2 | NCT02123615 | Jan → Jun 2016 | immunodeficiency disease | ASIS Corporation | Unknown | No outcome recorded |
| Phase 1/2 | NCT02112097 | Jan → Jun 2016 | psoriasis | ASIS Corporation | Unknown | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT03270059 | Oct 2017 → Dec 2027 expected | cranial nerve neuropathy, metastatic malignant neoplasm in the brain | OHSU Knight Cancer Institute | Recruiting | No outcome recorded |
| Phase 2 | NCT00659126 | Nov 2006 → Dec 2019 | metastatic malignant neoplasm in the brain, primary brain neoplasm | OHSU Knight Cancer Institute | Terminated | No outcome recorded Stop: Business |
| Phase 43 trials | ||||||
| Phase 4 | NCT02234375 | Jul 2017 → Dec 2018 | pulmonary embolism | Massachusetts General Hospital | Withdrawn | No outcome recorded |
| Phase 4 | NCT02163005 | Dec 2016 → Dec 2018 | drug pseudoallergy | Massachusetts General Hospital | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 4 | NCT02530931 | Mar 2016 → Sep 2020 | Meniere disease | University Hospital, Grenoble | Terminated | No outcome recorded Stop: Enrollment |
| Phase not applicable1 trial | ||||||
| — | NCT00103038 | Jun 2004 → May 2016 | lymphoma, malignant glioma, metastatic malignant neoplasm in the brain | OHSU Knight Cancer Institute | Completed | No outcome recorded |
| Comparator or background therapy11 trials | ||||||
| Phase 1 | NCT02390635 Background | Jul 2020 → Sep 2027 expected | acute promyelocytic leukemia | M.D. Anderson Cancer Center | Recruiting | No outcome recorded |
| Phase 1 | NCT02648009 Background | Apr 2016 → Apr 2027 expected | hypertensive disorder | Sunnybrook Health Sciences Centre | Recruiting | No outcome recorded |
| Phase 2 | NCT03649880 Background | Jun 2019 → Jan 2029 expected | IDH-wildtype glioblastoma | OHSU Knight Cancer Institute | Recruiting | No outcome recorded |
| Phase 2/3 | NCT01234870 Background | Jun 2010 → Jan 2012 | coronary atherosclerosis, myocardial ischemia | Northwestern University | Completed | No outcome recorded |
| Phase 4 | NCT02597543 Background | Nov 2015 → Jun 2016 | acute transplant rejection, chronic transplant rejection | Paul Kim | Completed | No outcome recorded |
| Phase 4 | NCT02255591 Background | Feb → Mar 2015 | — | University of Aarhus | Completed | Met primary |
| — | NCT02590497 Background | Mar 2016 → Oct 2017 | glioblastoma | Ohio State University Comprehensive Cancer Center | Withdrawn | No outcome recorded |
| — | NCT02948322 Background | Dec 2014 → Jun 2017 | acromegaly | Assistance Publique - Hôpitaux de Paris | Completed | No outcome recorded |
| — | NCT02270359 Background | Apr 2014 → Oct 2025 overdue | myocardial infarction | NYU Langone Health | Active not recruiting | No outcome recorded |
| — | NCT00660543 Comparator | Dec 2006 → Jun 2014 | adult glioblastoma | OHSU Knight Cancer Institute | Completed | No outcome recorded |
| — | NCT04809584 Background | — | prostate cancer | Stanford University | Approved for marketing | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 23 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Gadolinium | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02112097 ↗ |
| Known as | Gadolinium Magnevist (gadopentetate dimeglumine) | “Gadolinium Magnevist® (gadopentetate dimeglumine)” NCT02074293 ↗2“Gadolinium Magnevist® (gadopentetate dimeglumine)” NCT02112097 ↗ “Gadolinium Magnevist® (gadopentetate dimeglumine)” NCT02123615 ↗ |
| Modality | Diagnostic / imaging agent | “gadolinium-based contrast agent (GBCA)” NCT00103038 ↗ |
| Route | Intravenous | “GBCA IV approximately 1 minute and 50 seconds after start of 3T DCE-MRI” NCT00103038 ↗ |